FDA Approves Moderna's mRNA Flu Vaccine

The Food and Drug Administration (FDA) approved Moderna's mRNA flu vaccine on August 6, 2026. This vaccine is expected to improve upon the traditional flu vaccine, which has been largely unchanged for 80 years. The flu causes approximately 1 billion infections and 300,000 deaths annually. The new mRNA vaccine addresses the issue of the flu virus's rapid mutation, which often leads to a mismatch between the circulating virus and the vaccine produced using traditional methods. Unlike conventional vaccines, mRNA vaccines use genetic instructions to train the immune system to combat influenza, allowing for quicker production closer to flu season. In clinical trials, older adults who received the mRNA vaccine were found to be 27% less likely to contract the flu compared to those who received the standard vaccine. Public health experts are optimistic about mRNA technology, with ongoing research into mRNA vaccines for other diseases such as malaria and tuberculosis. However, the development of a universal flu vaccine remains a goal, as current vaccines must be updated annually due to the virus's mutations.